TrialDiabetes, obesity & metabolism2020

Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss.

Yuichi Sato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.